Compare KKR & Co Inc (KKR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KKR & Co Inc vs Recursion Pharmaceuticals Inc — how do they compare? KKR & Co Inc trades at $96.57 (market cap $87.07B), while Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B). The key difference: KKR & Co Inc is far larger — about 56.9× Recursion Pharmaceuticals Inc's market cap, and KKR & Co Inc pays a 0.77% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| KKR | RXRX | |
|---|---|---|
Market Cap | $87.07B | $1.53B |
Sector | Financials | Health |
52-Week High | $152.16 | $6.79 |
52-Week Low | $83.88 | $2.84 |
Enterprise Value | $12.59B | $946.50M |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KKR trades at $97.11, down 3.79% for the day, with a bullish technical signal and strong analyst backing. Recent earnings beat expectations in Q1 2026, and the firm is expanding through strategic ventures like a $1.3 billion renewable energy platform in South Korea and a $4.2 billion acquisition of EDF's North American operations. Financials show robust revenue of $19.21 billion in 2025 and a net income margin of 14.51%, though cash flow from operations has been volatile.
The outlook for KKR is positive, supported by a consensus price target of $120.75 and 89% buy ratings. Key opportunities include growth in renewable energy and private credit, while risks involve high leverage with long-term debt of $49.91 billion and dependence on capital market conditions. Investors should monitor the Q2 2026 earnings release on July 30, 2026, for further direction.
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
